Marshall Wace LLP Has $1.91 Million Position in Bioventus Inc. (NYSE:BVS)

Marshall Wace LLP lifted its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 38.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 332,291 shares of the company's stock after purchasing an additional 91,843 shares during the quarter. Marshall Wace LLP owned 0.42% of Bioventus worth $1,911,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Acadian Asset Management LLC bought a new stake in Bioventus during the first quarter worth about $28,000. Lazard Asset Management LLC bought a new stake in shares of Bioventus during the 1st quarter worth $40,000. HB Wealth Management LLC acquired a new stake in Bioventus in the second quarter valued at about $60,000. Burns Matteson Capital Management LLC bought a new position in Bioventus in the second quarter valued at about $67,000. Finally, SG Americas Securities LLC acquired a new position in Bioventus during the first quarter worth about $66,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Price Performance

BVS traded up $0.08 on Friday, reaching $11.75. The stock had a trading volume of 299,479 shares, compared to its average volume of 391,170. The company has a current ratio of 1.33, a quick ratio of 0.96 and a debt-to-equity ratio of 1.82. The company has a market capitalization of $930.20 million, a price-to-earnings ratio of -33.57 and a beta of 0.90. Bioventus Inc. has a fifty-two week low of $2.85 and a fifty-two week high of $12.41. The firm has a 50-day moving average of $9.66 and a 200-day moving average of $7.10.

Bioventus (NYSE:BVS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The business had revenue of $151.22 million during the quarter, compared to analyst estimates of $137.70 million. During the same quarter last year, the business earned $0.14 EPS. As a group, sell-side analysts anticipate that Bioventus Inc. will post 0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Craig Hallum raised their price target on shares of Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, September 27th. Canaccord Genuity Group increased their price objective on shares of Bioventus from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, August 13th.

Insider Transactions at Bioventus

In related news, Director John A. Bartholdson purchased 80,000 shares of Bioventus stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $8.55 per share, for a total transaction of $684,000.00. Following the transaction, the director now owns 6,913,857 shares of the company's stock, valued at approximately $59,113,477.35. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director John A. Bartholdson acquired 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The shares were bought at an average cost of $8.55 per share, with a total value of $218,025.00. Following the purchase, the director now owns 6,939,357 shares in the company, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John A. Bartholdson bought 80,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average cost of $8.55 per share, with a total value of $684,000.00. Following the purchase, the director now directly owns 6,913,857 shares of the company's stock, valued at $59,113,477.35. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 32.90% of the stock is owned by company insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.